Skip to main content
. 2020 Sep 10;3:100086. doi: 10.1016/j.ajpc.2020.100086

Fig. 1.

Fig. 1

Hazard Ratios of Clinical Endpoints for the Japan EPA Lipid Intervention Study (JELIS). Superscript 1 and 2 indicate primary and secondary prevention endpoints, respectively [60]. ∗P ​< ​0.05. Reprinted from The Lancet, 369, Yokoyama M, Origasa H, Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis, 1090–1098. Copyright 2007, with permission from Elsevier.